Stocks
Arcturus Therapeutics Holdings Financial Statements (ARCT) |
||||||||||
| Arcturus Therapeutics Holdingssmart-lab.ru | % | 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 07.08.2023 | 30.09.2023 | 31.12.2023 | 14.03.2024 | 08.05.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 9.57 | 43.4 | 34.0 | 28.2 | 32.6 | 138.2 | |||
| Operating Income, bln rub | -55.4 | -19.3 | -15.1 | -11.1 | -30.4 | -76.0 | ||||
| EBITDA, bln rub | ? | -51.4 | -19.3 | -15.1 | -10.3 | -25.5 | -70.2 | |||
| Net profit, bln rub | ? | -52.6 | -16.2 | -8.57 | -8.57 | -26.8 | -60.2 | |||
| OCF, bln rub | ? | 50.8 | -32.4 | -0.545 | -5.56 | -38.5 | ||||
| CAPEX, bln rub | ? | 0.354 | 0.981 | 0.837 | 0.240 | 2.06 | ||||
| FCF, bln rub | ? | 50.5 | -33.4 | -1.38 | -5.80 | -40.6 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 64.9 | 62.7 | 49.1 | 38.5 | 63.0 | 213.3 | ||||
| Cost of production, bln rub | 52.7 | 0.800 | 0.000 | 0.815 | 5.41 | 7.03 | ||||
| R&D, bln rub | 52.7 | 51.1 | 36.6 | 26.8 | 53.6 | 168.1 | ||||
| Interest expenses, bln rub | 0.000 | 0.020 | 0.000 | 0.004 | 0.000 | 0.024 | ||||
| Assets, bln rub | 430.6 | 457.7 | 429.4 | 429.4 | 418.8 | 418.8 | ||||
| Net Assets, bln rub | ? | 285.2 | 280.1 | 281.6 | 278.5 | 264.0 | 264.0 | |||
| Debt, bln rub | 32.2 | 47.0 | 25.9 | 30.2 | 31.9 | 31.9 | ||||
| Cash, bln rub | 323.5 | 311.9 | 347.0 | 347.0 | 288.4 | 288.4 | ||||
| Net debt, bln rub | -291.3 | -264.9 | -321.1 | -316.8 | -256.5 | -256.5 | ||||
| Ordinary share price, rub | 28.7 | 25.6 | 31.5 | 31.5 | 33.8 | 19.0 | ||||
| Number of ordinary shares, mln | 26.6 | 26.6 | 26.6 | 26.6 | 26.9 | 26.9 | ||||
| Market cap, bln rub | 762 | 679 | 840 | 840 | 908 | 510 | ||||
| EV, bln rub | ? | 471 | 414 | 518 | 523 | 651 | 254 | |||
| Book value, bln rub | 285 | 280 | 282 | 279 | 264 | 264 | ||||
| EPS, rub | ? | -1.98 | -0.61 | -0.32 | -0.32 | -1.00 | -2.24 | |||
| FCF/share, rub | 1.90 | -1.26 | 0.00 | -0.05 | -0.22 | -1.51 | ||||
| BV/share, rub | 10.7 | 10.5 | 10.6 | 10.5 | 9.82 | 9.82 | ||||
| EBITDA margin, % | ? | -537.2% | -44.5% | -44.5% | -36.5% | -78.2% | -50.8% | |||
| Net margin, % | ? | -549.4% | -37.4% | -25.2% | -30.4% | -82.3% | -43.6% | |||
| FCF yield, % | ? | 16.5% | 20.2% | -2.32% | -2.49% | 1.09% | -7.95% | |||
| ROE, % | ? | 28.4% | 35.5% | -9.44% | -9.55% | -39.5% | -22.8% | |||
| ROA, % | ? | 18.8% | 21.7% | -6.19% | -6.19% | -24.9% | -14.4% | |||
| P/E | ? | 9.40 | 6.84 | -31.6 | -31.6 | -8.71 | -8.48 | |||
| P/FCF | 6.06 | 4.96 | -43.1 | -40.2 | 91.8 | -12.6 | ||||
| P/S | ? | 2.90 | 2.32 | 5.04 | 5.22 | 7.98 | 3.69 | |||
| P/BV | ? | 2.67 | 2.42 | 2.98 | 3.01 | 3.44 | 1.93 | |||
| EV/EBITDA | ? | 24.7 | 11.6 | -4.95 | -5.23 | -6.12 | -3.61 | |||
| Debt/EBITDA | -15.3 | -7.42 | 3.07 | 3.17 | 2.41 | 3.65 | ||||
| R&D/CAPEX, % | 14 878% | 5 207% | 3 204% | 22 322% | 8 167% | |||||
| CAPEX/Revenue, % | 3.70% | 2.26% | 0.00% | 2.97% | 0.74% | 1.49% | ||||
| Arcturus Therapeutics Holdings shareholders | ||||||||||
